Anti-Aging Drug Discovery Targeting p38 MAPK

The p38 mitogen-activated protein kinase (MAPK) pathway is a signaling cascade that regulates various cellular processes, including inflammation, cell cycle progression, and apoptosis. Persistent activation of p38 MAPK leads to the production of pro-inflammatory cytokines. In aging, dysregulation of the p38 MAPK pathway has been implicated in chronic inflammation, cellular senescence, and the development of age-related diseases.

Fig. 1 The mechanism of action of p38 MAPK. (Shamsnia HS, et al., 2023)

CD BioSciences is a trusted drug discovery company with specialized expertise in targeting key molecular pathways involved in the aging process. Our research services focus on the p38 MAPK signaling pathway, a critical regulator of cellular responses to stress and inflammation.

How Do We Develop Anti-Aging Drugs Targeting p38 MAPK?

Target validation

We help clients conduct rigorous target validation studies to confirm that the p38 MAPK pathway is indeed a relevant and druggable target for age-related diseases. We quantify the expression of genes in the p38 MAPK pathway in models of aging and age-related diseases.

Drug screening and optimization

We use high-throughput screening (HTS) to identify potential drugs that target the p38 MAPK pathway. We engage in rigorous optimization processes to enhance their efficacy and selectivity. We also help clients employ a variety of assays to measure the inhibition of p38 MAPK activation, including fluorescence-based assays, radiometric assays, and label-free detection methods.

In vitro and In vivo testing

Our team conducts extensive testing using both in vitro and in vivo models to assess the pharmacodynamics and pharmacokinetics of the drug candidates. We help clients measure cell viability and proliferation in response to anti-aging drugs targeting p38 MAPK. We use aging animal models to assess the effects of drugs on lifespan and healthspan. We also evaluate cognitive and physical functions (e.g., mazes for cognitive function, grip strength tests) to determine whether anti-aging drugs improve age-related decline.

Targeting p38 MAPK in Aging-Related Diseases

CD BioSciences helps clients develop anti-aging drugs targeting the p38 MAPK pathway that holds promise for the treatment of various age-related diseases, including:

• Aging-related neurodegenerative diseases. The p38 MAPK pathway plays a key role in neuroinflammation, a hallmark of Alzheimer's disease. We help clients develop drugs that modulate this pathway to reduce neuroinflammation and improve cognition
• Aging-related cardiovascular diseases. Inflammation is a major contributor to cardiovascular diseases. CD BioSciences aims to help clients develop drugs that reduce inflammation and prevent the progression of aging-related cardiovascular diseases by targeting the p38 MAPK signaling pathway.

Features of Our Anti-Aging Drug Discovery Services

• Customized drug discovery services. Our team collaborates closely with clients to develop customized research strategies to meet specific needs and objectives.
• Comprehensive support. We employ a variety of drug discovery tools to enhance our research capabilities. We provide comprehensive support, guiding our clients through every stage of the drug discovery process.

With an innovative approach and comprehensive services, CD BioSciences is committed to helping clients develop safe and effective anti-aging drugs that specifically target the p38 MAPK pathway. If you are interested in our services, please feel free to contact us or make an online inquiry.

References

1. Shamsnia HS, et al. Impact of curcumin on p38 MAPK: therapeutic implications. Inflammopharmacology, 2023, 31 (5): 2201-2212.
2. Yuan W, et al. Modulating p38 MAPK signaling by proteostasis mechanisms supports tissue integrity during growth and aging. Nat Commun, 2023, 14 (1): 4543.